![]() |
|
|
Vol. 290, Issue 1, 146-152, July 1999
Departments of Pharmacology (E.A.S., R.Z.G., P.D., E.P.A., M.R.R.)
and Pediatrics (M.R.R.), College of Physicians and Surgeons of
Columbia University, New York, New York
We studied the electrophysiological effects of LU111995 (1-15 mg/kg
p.o.) in conscious dogs with chronic atrioventricular block and
ventricular pacing at 50 to 130 beats/min. LU111995 had no effects on
idioventricular rhythm, QRS duration, and ventricular conduction time.
It significantly prolonged Q-T interval (by 5-8%) and
effective refractory period (ERP) (by 5-12%) with the maximal effect
at 4 h after a 10 mg/kg dose. At 10 and 15 mg/kg, it increased the
ERP/Q-T ratio. In vitro, the effects of LU111995 (1 × 10
7 to 1 × 10
5 M) on
action potentials of Purkinje fibers (PFs) and M cells were studied at
cycle lengths (CL) of 300 to 2000 ms. It had no effects on maximum
diastolic potential and action potential amplitude in either tissue.
High concentrations induced a moderate, rate-independent decrease of
max in M cells. In PFs and M cells,
it produced reverse use-dependent lengthening of action potential
duration (APD). In PFs at long CL, the drug exhibited a biphasic
concentration-dependent effect on APD: maximum prolongation (by 26% at
a CL of 2000 ms) was attained at 1 × 10
6
M, and a decrease of APD occurred at higher concentrations.
In M cells, the maximum effect on APD occurred at 3 × 10
6 M. Early afterdepolarizations were seen
in 50% of M cell preparations but only at CL of 2000 ms. Triggered
activity did not occur. In summary, LU111995 prolongs the Q-T interval
to a limited degree and is not arrhythmogenic over the physiological
range of CLs.